• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia

Posted on: Monday, 29 June 2009, 10:20 CDT

JACKSONVILLE, Fla., June 29 /PRNewswire-USNewswire/ -- On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the development of certain malignancies. The authors themselves, and the accompanying editorial, cautioned against over-interpretation of their limited data and analyses, which precluded them from drawing any firm conclusions. For example, there were contradictory findings among the studies, patient populations were not always comparable, and the duration of observation was short. Nonetheless, since the relationship of type 2 diabetes to cancer is of critical importance, further study is warranted.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b )

The American Association of Clinical Endocrinologists (AACE) does not recommend that the use of any insulin be changed. AACE supports further research into the effectiveness and safety of all diabetes therapies and will continue to update recommendations as further data becomes available. Individual patient concerns should be discussed with their physicians.

For more information, including links to the EASD press release and articles, click here: http://www.aace.com/newsroom/alerts/index.php.

About AACE

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.

For more information, contact Bryan Campbell of the American Association of Clinical Endocrinologists at 904-353-7878 ext. 122, or bcampbell@aace.com.

SOURCE American Association of Clinical Endocrinologists

Source: PR Newswire

More News in this Category